New GSMA Report Highlights Integral Role of Mobile IoT Networks in 5G Future
The GSMA today issued a new report, ‘NB-IoT and LTE-M in the 5G context’, highlighting the integral role that licensed Mobile IoT networks, such as NB-IoT and LTE-M, will play in the 5G future and, in particular, the development of ‘massive IoT’. Massive IoT is one of three principle 5G use cases, alongside critical communications and enhanced broadband, that will enable developments such as smart cities and industrial automation. NB-IoT and LTE-M will be fundamental to the development of massive IoT and in supporting and complementing 5G’s myriad use cases and applications. Leading operators including AT&T, Deutsche Telekom, KDDI, Orange and Vodafone are committed to deploying these networks as part of their future 5G massive IoT strategies.
“While people often associate 5G with super-fast mobile broadband speeds, it will also serve a variety of use cases often with diametrically opposed requirements such as low data rates and long battery life as with the case of Mobile IoT,” commented Alex Sinclair, Chief Technology Officer, GSMA. “Licensed NB-IoT and LTE-M networks are already delivering trusted connectivity today to millions of devices around the world, and these networks will continue to be a fundamental component of our 5G future ushering in an era of massive IoT.”
Mobile operators, in collaboration with global vendors and developers, are launching Mobile IoT networks today to support applications such as smart metering, smart logistics and smart environmental monitoring, but also as a core component of their long-term strategy and commitment to 5G IoT standards. Licensed Mobile IoT networks are standardised by 3GPP and are designed to support cellular IoT applications that are low cost, use low data rates, require long battery lives and often operate in remote and hard-to-reach locations such as industrial asset tracking, safety monitoring or water and gas metering. To date, 24 mobile operators have commercially launched 48 Mobile IoT networks worldwide across both NB-IoT and LTE-M technologies. According to GSMA Intelligence forecasts, by 2025 there will be 3.1 billion cellular IoT connections, including 1.8 billion licensed LPWA connections.
3GPP is set to complete Release 15 in June, which will include NB-IoT and LTE-M as 5G Mobile standards. 3GPP will also not include any additional LPWA requirements in its next release, meaning that NB-IoT and LTE-M will coexist with other 3GPP technologies and fulfil long-term 5G LPWA requirements. NB-IoT and LTE-M networks will deliver connectivity to billions of new devices and provide comprehensive IoT connectivity in the 5G era.
For more information on GSMA’s Mobile IoT Initiative and to download the report ‘NB-IoT and LTE-M in the 5G context’, please go to: https://www.gsma.com/iot/mobile-iot-5g-future/
“Low-Power Wide-Area networks hold the key to global deployment of IoT devices and applications that will only grow with 5G,” said Chris Penrose, President, Internet of Things Solutions, AT&T. “Our investment in Massive IoT in the U.S. and Mexico marks another step forward on our path to 5G with 3GPP standardised technology and licensed spectrum.”
“Deutsche Telekom fully supports GSMA’s statement of the integral role of Mobile IoT networks in the 5G future. Looking further, LPWA technologies such as NB-IoT have been paving the way for 5G and will be an important part of the 5G technologies – with its virtualised core networks already implemented at Deutsche Telekom, it is reality today for us,” said Dr. Ingo Hofacker, SVP, IOT, Deutsche Telekom.
“The GSMA report clarifies the ambiguity in the relationship between LPWA and 5G by highlighting that the existing LPWA 3GPP technologies are set to coexist with other 3GPP 5G technologies and fulfil longterm LPWA requirements. For the age of IoT and 5G, KDDI will establish Open Labs to facilitate the rapid development of innovative services in Tokyo in the summer of 2018,” said Keiichi Mori, Managing Executive Officer, GM, IoT Business Development Division.
Luke Ibbetson, Head of R&D for Vodafone Group and Chair of the GSMA NB-IoT Forum, said: “Vodafone pioneered the development of NB-IoT and already has networks in nine countries. We strongly believe that NB-IoT, the first 5G internet of things network, will be the foundation for a society where people and businesses are far more connected to and informed about the world around them.”
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 300 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai, Mobile World Congress Americas and the Mobile 360 Series of conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Personalis, Inc. to Present at Advances in Immuno-Oncology Congress UK 201920.5.2019 10:05:00 EEST | Tiedote
Personalis, Inc., a leader in advanced genomics for cancer, today announced that the company will present at Advances in Immuno-Oncology Congress UK 2019 in London on May 21st at 11:00 AM BST. The presentation, entitled “Advancing Precision Oncology Biomarker Discovery with a Multi-dimensional Immunogenomics Platform,” will introduce Personalis’ new universal cancer immunogenomics platform, ImmunoID NeXT™. In addition to an overview, the presentation will introduce preliminary data from an ongoing study in which this platform is being used to evaluate IO-related biomarkers and potential tumor escape mechanisms in a cohort of melanoma patients treated with anti-PD-1 therapy. ImmunoID NeXT™ is the first platform to provide comprehensive analysis of both a tumor and its immune microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one. This maximizes the
New Study Evaluates Ability of Masimo SpHb® (Noninvasive Hemoglobin) to Estimate Timing for Invasive Measurement to Detect Anemia During Surgery20.5.2019 10:00:00 EEST | Tiedote
Masimo (NASDAQ: MASI) announced today the results of a study published in BMC Anesthesiology in which clinicians at Peking Union Medical College in Beijing evaluated the ability of noninvasive and continuous hemoglobin monitoring with Masimo SpHb® to help clincians estimate when to conduct invasive hemoglobin measurement to detect possible anemia in patients undergoing spine or cytoreductive surgery.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190520005244/en/ Masimo Radical-7® with SpHb® (Photo: Business Wire) Noting that because of the “invasive, time-consuming and intermittent” nature of invasive blood sampling, clincians often forgo these “objective indications” when making transfusion decisions during surgery, Dr. Tang and colleagues sought to determine whether noninvasive, continuous hemoglobin monitoring could aid clinicians in estimating when it might be appropriate to perform an invasive measurement. They enroll
Cleo to Showcase End-to-End Approach to Ecosystem Integration at Gartner AADI in London20.5.2019 10:00:00 EEST | Tiedote
Gartner’s Application Architecture, Development & Integration (AADI) Summit returns to London to provide strategies for solving the pervasive challenges of orchestrating workflows between external B2B and application ecosystems with internal business systems. Cleo, the global leader in ecosystem integration solutions, will be exhibiting in Booth S3 to demonstrate how successful organisations leverage its “outside-in” approach to create seamless end-to-end workflows and help optimize business processes. The Gartner AADI 2019 event, taking place 20-21 May at Park Plaza Westminster, is designed to empower IT and business professionals in transforming their application architecture, agile development, and integration strategies. The event’s focus on application strategies and data processes in the era of the cloud highlights the need for better ways to execute application integration, an inescapable challenge in today’s business landscape. According to the 2019 State of Ecosystem and Integ
Commerzbank Partners with GTC to Further Digitize and Automate its Trade Finance Business20.5.2019 07:00:00 EEST | Tiedote
Commerzbank has entered into a strategic partnership with GlobalTrade Corporation (GTC), a leading Canadian application services provider of innovative multi-bank trade finance solutions. The bank plans to utilise GTC’s @GlobalTrade™ platform to strengthen its digital trade finance product range. As one of Europe’s leading trade finance banks, Commerzbank holds the digitalisation and automation of processes as key priorities. This partnership leverages Commerzbank’s unique network footprint and GTC’s multi-bank technology, coupled with SWIFT connectivity, to meet the trade finance needs of corporate clients across the globe more efficiently and effectively. “We are very pleased to have found a strategic and reliable business partner in the trade finance business in GTC. Together we will provide digital, multi-bank trade finance solutions to our clients as well as an expanded range of trade products,” said Klaus Josef Müller, Head of Trade Finance and Cash Management Product Management
New Exploratory Data from VARSITY, First Head-to-Head Ulcerative Colitis Biologic Study Which Demonstrated Superiority of Vedolizumab to Adalimumab in Clinical Remission at Week 52, Presented at 2019 Digestive Disease Week®20.5.2019 03:16:00 EEST | Tiedote
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced further results from the Phase 3b head-to-head VARSITY study, which demonstrated that the gut-selective biologic vedolizumab (Entyvio®) was superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira®) in achieving clinical remission* at week 52 in patients with moderately to severely active ulcerative colitis (UC).1 New exploratory data showed that a greater proportion of patients receiving vedolizumab intravenous (IV) achieved clinical response** at week 14 compared to those treated with adalimumab subcutaneous (SC), 67.1% vs. 45.9% respectively. A separation between the treatment groups was seen as early as week 6, favoring vedolizumab. These results were announced in a Distinguished Abstract Plenary Lecture Presentation at the 2019 Digestive Disease Week® (DDW) annual scientific meeting (May 18-21 in San Diego, CA), one of 18 Takeda sponsored vedolizumab abstracts accep
Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought19.5.2019 22:15:00 EEST | Tiedote
ResMed (NYSE: RMD, ASX: RMD) today revealed several demographic and clinical factors affect adherence to PAP (positive airway pressure) therapy, according to a study it presented at the American Thoracic Society's ATS 2019 International Conference. The study found significant differences in one-year adherence between people of different ages and disease severity levels: Men with sleep apnea are 8.5 percentage points more likely to stay adherent on PAP therapy than women. People over age 60 were 7.3 percentage points more adherent than the entire study cohort (77.7% vs. 70.4%). People with self-reported severe sleep apnea were 78% adherent at the one-year mark, compared to 70.5% of those with self-reported moderate sleep apnea, and 65.2% of those with mild sleep apnea. “Sleep specialists, pulmonologists, and primary care physicians should heed these results and ensure that their younger, female, and more mildly diagnosed patients have the proper supports to stay on therapy,” said Adam B
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme